Asia
The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018.
A study out of China in 150 hospitalized patients conducted at 16 sites showed the medication did not help patients clear the virus better than standard care. It was also significantly more likely to cause serious side effects.
Global pharma and life sciences companies provide updates on their business operations and pipelines.
It’s likely that more companies and universities will add additional assets as time goes on.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
A preliminary analysis of late-stage trial data shows that BeiGene’s investigational checkpoint inhibitor tislelizumab is hitting the mark as a potential first-line treatment in patients with non-squamous non-small cell lung cancer.
Although the COVID-19 death toll has not yet reached the numbers of H3N2, it still continues to climb.
It was a very busy week for clinical trial news. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
China’s CanSino Biologics is advancing its COVID-19 vaccine candidate into Phase II, putting the company ahead of others in the race against the novel coronavirus.
PRESS RELEASES